Medtronic Analyst Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
60 "major" launches planned for 2011: Medtronic plans to launch 60 "major" new products within the next year, including magnetic-resonance-imaging-safe implants, CEO Bill Hawkins told analysts at a June 7 investor and analyst meeting in New York. He noted Medtronic has 25 PMAs under review at FDA, as well as approximately 30 "major" clinical trials. "I have been with the company for nine years, and I cannot remember a time when our pipeline has been as robust and full," Hawkins said. "We are investing roughly 9[%] to 10% of our sales dollars in organic R&D, which translates into about $1.6 billion.